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ABSTRACT 
A microcrystalline test for the detection of 4-methylmethcathinone (mephedrone), benzylpiperazine (BZP) and 5,6-
methylenedioxy-2-aminoindane (MDAI) using aqueous solutions of mercury chloride is described. Each of the 
compounds investigated formed specific drug-reagent crystals within minutes. The uniqueness of the test was 
confirmed by comparison of the microcrystalline response to that of other psychoactive stimulants and a common 
cutting agent. The limit of detection and cut-off levels for reference standards were established to 3 g/L and 5 g/L 
for mephedrone, 0.5 g/L for MDAI and 0.2 g/L and 0.3 g/L for BZP, respectively. Various mixtures of standards of 
either mephedrone, BZP or MDAI combined with caffeine were investigated for their microcrystalline response. 
Results showed that simultaneous detection of drug and cutting agent was possible with the concentrations tested 
but were dependant on the ratio of drug to cutting agent. BZP could be detected alongside caffeine from as low as 
20 % (v/v), MDAI from 40 % (v/v) and mephedrone from 50 % (v/v) and higher. Finally, seven samples of online 
purchased ‘legal highs’ were analysed using the developed test and the findings were compared to FTIR and GC-
MS results. It was shown that 6 out of 7 samples did not contain the advertised active ingredient. Five samples 
consisted of BZP, caffeine and 1-[3-(Trifluoromethyl)phenyl]piperazine (3-TFMPP). The microcrystalline tests 
carried out on these samples showed positive results for both BZP and caffeine without interference from other 
substances present. 
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INTRODUCTION 
The internet has recently been flooded with new synthetic recreational drugs, so called ‘legal highs’, easily 
available for everyone to buy. Substances are commonly advertised as fertiliser for plants, research chemicals or 
bath salts but are being used to replace more strongly controlled psychoactive stimulants like MDMA or cannabis. 
The UK is continuously banning the legal use of novel emerging designer drugs and controlling them under the 
different amendments of the Misuse of Drugs Act 1971 [1-3]. 
In 2010 various publications investigated the homogeneity of internet bought samples [4-6] and revealed that on 
many occasions the advertised active ingredient was not actually sold. Instead, often dangerous cocktails of illicit 
drugs bulked out with legal stimulants like caffeine were purchased. Recently banned substances like 4-
methylmethcathinone (mephedrone), benzylpiperazine (BZP) and 1-[3-(Trifluoromethyl)phenyl]piperazine (3-
TFMPP) have been found in supposedly legal ‘highs’. Second generation legal highs like 5,6-methylenedioxy-2-
aminoindane (MDAI) or 5-iodo-2-aminoindane (5-IAI) emerged after the bans of 2009 and ‘10 and were still legally 
available in the first half of 2011 [Figure 1]. Characterisation and analysis of novel drugs is difficult since adequate 
reference standards are often not easily available [6]. Given recent trends in the legislation regarding legal highs, 
second generation substances could be banned in the near future. 
Publications on quick and simple non-instrumental analyses such as colour or microcrystalline tests for these new 
drugs are sparse. It has been reported that existing colour tests are not sensitive enough for some of the new 
drugs [7,8]. A colour test to detect mephedrone using Zimmermann’s reagent as well as a simple TLC procedure 
using ninhydrin reagent for visualisation have been communicated [9]. Stimulants like BZP and 3-TFMPP have 
been analysed using well established colour test reagents, such as Simon’s and Marquis’, which are widely used 
by drug enforcement investigators [7].  The colour responses were reported to be similar to those of other 
stimulants like the amphetamines. Similarities to existing compounds are not surprising since a change in colour is 
always caused by a functional group rather than the molecule as a whole. Consequently, tests can be inconclusive 
and results easily misinterpreted. 
Microcrystalline identification of drugs of abuse has been used for a long time in forensic drug analysis. The 
simplicity of the test layout paired up with the uniqueness of the results obtained provides a powerful tool when 
analysing unknown substances. Microcrystalline tests are direct tests as the analyte molecule itself becomes a part 
of the crystal structure and therefore a specific crystal habit is observed for many compounds [10]. 
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It has been previously reported that compounds other than the drug of interest present in the tested sample can 
influence the microcrystalline test result [11,12]. Cutting agents like caffeine can crystallise with the reagent or 
hinder crystallisation and therefore result in distortion of the overall microcrystalline test appearance. In a recent 
publication Nelson et al. presented results were the effects of the adulterants caffeine and lidocaine on developing 
cocaine tetrachloroaurate microcrystals were investigated [12]. It was reported that an increasing adulterant 
concentration influenced the cocaine-reagent crystals by changing their appearance. Furthermore, differences in 
crystal habit were detected depending on the adulterant added which allowed some sort of identification of cutting 
agent present in a model street cocaine hydrochloride sample. 
 
In this paper a simple microchemical identification test for mephedrone, BZP and MDAI using mercury chloride as a 
reagent is proposed. Mercury chloride has been reported and used as a reagent for microcrystalline tests to detect 
drugs of abuse like methadone and diamorphine [13,14]. Tests were developed and carried out using standards. 
Results were confirmed using internet bought samples, the composition of which had been analysed and published 
previously [6].  
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Figure 1 
Structures of selected designer drugs and one cutting agent 
 
MATERIALS AND METHODS 
Chemicals and Materials 
Mephedrone hydrochloride (> 98.5 %) was purchased from ReseaCHEM (Burgdorf, Switzerland), 5,6-
Methylenedioxy-2-aminoindane freebase (99.3 %) was from LGC GmbH (Luckenwalde, Germany), 1-
benzylpiperazine freebase (> 97 %) was from Fluka (Steinheim, Germany). 1-[3-(Trifluoromethyl)phenyl]piperazine 
hydrochloride, cocaine hydrochloride, ephedrine hydrochloride (99 %), procaine hydrochloride, (±)-3,4-
methylenedioxymethamphetamine hydrochloride (MDMA), D-amphetamine sulphate, DL-amphetamine sulphate, L-
amphetamine freebase, (+)-methamphetamine hydrochloride, (±)-methadone hydrochloride and caffeine were 
purchased from Sigma-Aldrich (Gillingham, UK). (-)-Ephedrine sulphate (98 %) was from Acros Organics (New 
Jersey, USA). Mercury dichloride (> 99.5 %) and mercury (II) iodide (> 99 %) were from Sigma-Aldrich. All water 
used was deionised to 18.2 MΩ resistance using an Elga Labwater Purelab flex system (High Wycombe, UK). 
Methanol (HPLC-grade) was obtained from Fisher Scientific (Loughborough, UK). 
Four legal high samples were purchased online in August 2010 as MDAI, 5-IAI, Benzo fury and NRG-3 including a 
free sample of E2 from www.benzofury.me.uk; two further MDAI labelled samples were purchased in October 2010 
from www.VIPlegals.com and www.wide-mouth-frog.com. 
Microcrystalline tests were carried out on standard microscope glass slides purchased from Fisher Scientific and 
used as obtained.  
 
Microcrystalline test method 
Drug standards were prepared as aqueous solutions at concentrations of 10 g/L for mephedrone and 1 g/L for 
MDAI and BZP. MDAI was dissolved in methanol first and then diluted in water resulting in an overall solvent 
content of 10 % methanol. Other psychoactive stimulants were tested by using a few grains of the drug standard 
dissolved in 10 µL water on a microscope slide. 
The reagent was an aqueous solution of mercury chloride at a concentration of 10 g/L. Tests on MDAI were carried 
out with 10 g/L mercury chloride solutions containing 10 % methanol. Mercury iodide was dissolved in 100 % 
methanol as were the drug standards tested with it. 
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Microcrystalline tests were set up by mixing 10 µL of drug solution with 10 µL of the reagent on a glass slide. 
Nucleation was assisted and therefore crystallisation encouraged by gently swirling a plastic pipette tip a few times 
within the freshly mixed drop. After the initial encouragement tests were not further disturbed.  
Drug and reagent controls were carried out alongside all experiments by applying the respective volumes of drug or 
reagent solution only to slides, assisting nucleation with a pipette tip and observing crystallisation patterns 
throughout and at the end of the test. 
Progress of the microcrystal development was observed with a Meji ML 5000 microscope (Axbridge, UK) under low 
and high magnification using calibrated transmitted light microscopy and phase contrast microscopy set for Kohler 
illumination at 400x overall magnification. 
Images were taken using a Canon EOS Rebel T2i digital SLR camera fitted with a Meiji Techno adapter ring, 
camera attachment and 1.9 x magnification photo eye piece.   
  
RESULTS & DISCUSSION 
The reaction between mephedrone, MDAI, BZP and mercury chloride was carried out independently. Descriptions 
of the obtained crystals are listed in table 1 along with the results of mercury chloride combined with other 
stimulants.  
 
The mephedrone test 
The mephedrone-reagent crystals formed paddlewheel clusters consisting of several square-cut blades [Figure 2a]. 
Crystal clusters were three-dimensional shapes that grew in length, depth and height within the dimensions of the 
applied droplets. The speed of growth varied between 1 and 30 minutes depending on the drug concentration 
tested, with an increasing crystal growth rate as concentration increased.  
It appeared that crystallisation consistently originated from a central point of nucleation. Crystal clusters were 
denser and less translucent when nucleation was unassisted, whereas when nucleation was assisted crystals 
appeared faster and in a more organised manner developing along the movement lines forming chains of blades 
like barbwire. Then the central point of nucleation was of longitudinal dimension and only a few paddlewheel 
clusters could be detected. 
It was also observed that too vigorous movement during assisted nucleation would disturb the orientation of the 
densely packed chain, nuclei would be separated from the chain and single blades of varying dimensions would 
grow. 
At concentrations lower than approximately 5 g/L fewer crystals formed. Crystal clusters were sparse and single 
blades were more common. Premature paddlewheel structures consisting of only a few pointy plates appeared 
within the periphery of the drop. 
It was important to observe the test periodically during the development as mephedrone formed drug-only crystals 
easily when in excess covering already formed drug-reagent crystals which made the identification of mephedrone 
increasingly difficult.  
Mephedrone controls crystallised covering the test area as transparent scales of joint plates which had no 
resemblance to the mephedrone-reagent crystals. 
 
The MDAI test 
The MDAI freebase standard was not soluble in water and therefore the substance was dissolved in methanol and 
subsequently diluted in water resulting in an overall methanol content of 10 % (v/v). The mercury chloride reagent 
used to develop the MDAI tests was also prepared in 10 % (v/v) methanol to prevent precipitation before forming 
microcrystals. The low percentage of methanol did not speed up the evaporation of the test significantly and 
crystallisation was not hindered. 
MDAI freebase and mercury chloride formed flat serrated blades of varying dimensions, which became more 
irregular with increasing size [Figure 2bi]. Smaller crystals would grow as single blades and larger crystals would 
develop as predominantly two-dimensional bunch structures which would spread out fanwise from a single joining-
point. Small clusters of single or joint blades would break off while the test drop was still wet. Upon drying larger 
blade structures would dehydrate leaving straw-like crystal bunches which could be unequivocally identified at low 
magnifications despite the distortion. 
Crystals grew within 60 seconds after assisted nucleation along the trail the pipette had left but would also appear 
over time in the non-assisted regions of the drop. 
MDAI freebase controls showed large irregular transparent plates of drug crystals forming as crusts from the edges 
of the drop. 
At the time of conducting this study an MDAI hydrochloride standard was not available. MDAI freebase was 
converted into its hydrochloride salt by adding concentrated hydrochloric acid to MDAI solutions. After thoroughly 
mixing for 20 seconds using a vortex mixer tests were carried out using aqueous mercury chloride reagent 
solutions. After a couple of minutes trapezoidal blades grew within the test area [Figure 2bii]. MDAI hydrochloride 
controls crystallised as random skeletons covering the test area. 
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Overall, MDAI freebase and MDAI hydrochloride resembled each other by forming crystal blades when mixed with 
mercury chloride. 
 
The benzylpiperazine test 
BZP and mercury chloride formed transparent flat square-cut plates. Towards the edges the crystals affected the 
passage of light waves which created an appearance of colour. The feature was enhanced when observing the 
BZP-reagent microcrystals using phase contrast microscopy [Figure 2c]. 
A concentration of 10 g/L of BZP resulted in instantaneous white precipitation when mixed with the reagent 
masking any potential crystal formation. A ten fold dilution enabled the detection of microcrystals as seen in figure 
2c. Nucleation was assisted but if the motion was carried out too vigorously, crystallisation would turn into a rapid 
precipitation of drug and reagent hindering observation of crystals. At lower concentrations the force of assistance 
had less impact. When nucleation was not assisted fewer square-cut plates grew and were masked by a thin layer 
of crystal scales which made identification more difficult compared to assisted nucleation. 
Crystals grew within 30 seconds after assisted nucleation on the trails of the pipette swirls. After a couple of 
minutes crystals would appear anywhere within the test area but not necessarily originating from the edge of the 
drop. At the tested concentrations crystals could be identified with confidence even when the test was fully 
developed and the area dried out. 
The size and quantity of the crystals appeared to be related to the concentration of BZP. When the concentration 
was decreased, approaching the limit of detection, significantly fewer but larger crystals would grow. Some large 
square plates could be easily spotted at lower magnifications despite excess reagent crystals. 
BZP controls would grow as densely packed, mainly undefined bushes covering the whole test area by forming a 
crusting layer of irregular crystallisation.  
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Figure 2 
Microcrystals formed with mercury chloride and a) mephedrone (c = 10 g/L), bi) MDAI freebase (c = 1 g/L), bii) MDAI hydrochloride (c = 1 g/L) 
and c) BZP (c = 1 g/L) 
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Confirmation of the uniqueness of the test 
Structurally similar drugs as well as other psychoactive stimulants were tested using the mercury chloride reagent 
to confirm the uniqueness of the above described crystals. All resulting crystal responses are summarised in Table 
1 and a few selected shown in Figure 3. 
The test results did not show crystal patterns similar to those obtained with mephedrone, MDAI and BZP. The 
observed crystal structures for all other tested substances were in accordance with the results reported by Fulton 
and Clarke in 1969 [13,14]. The microcrystalline response of 3-TFMPP, MDMA and γ-hydroxybutyric acid with 
mercury chloride has not been published previously. At higher concentrations some drugs showed similar looking 
crystallisation patterns which may be explained by the structural similarity of the tested drugs. 
 
Table 1 
Microcrystal description of selected psychoactive stimulant drugs tested with mercury chloride 
Drug Crystal description Cross reference  
Figure 2 
3-TFMPP white precipitation, no crystal formation - 
BZP square plates a 
Caffeine long needles b 
Cocaine no crystal formation - 
D-Amphetamine dense rosettes and bunches of hair like needles c 
DL-Amphetamine smudge rosettes d 
Ephedrine hydrochloride skeletonised crosses e 
Ephedrine sulphate bunches of hair like needles f 
γ-hydroxybutyric acid no crystal formation - 
L-Amphetamine white precipitation with some plates - 
MDAI bunches of serrated blades g 
MDMA no crystal formation - 
Mephedrone paddlewheels and rosettes of blades h 
Methamphetamine skeletonised and branched rods and plates i 
Procaine no crystal formation - 
 
 
Figure 3 
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Microcrystalline response of selected psychoactive stimulant tested with mercury chloride as reagent; a) BZP, b) caffeine, c) D-amphetamine, d) 
DL-amphetamine, e) ephedrine hydrochloride, f) ephedrine sulphate, g) MDAI, h) mephedrone, i) methamphetamine. 
Footnote: image a) was taken at 76 x magnifications, images b) to i) were taken at 19 x magnifications. 
 
 
 
Limit of detection for the microcrystalline test 
The limit of detection was determined by approaching the concentration where no specific drug-reagent crystals 
would form. Cut-off values were set at the lowest concentration tested which unmistakably resulted in drug-reagent 
crystals as recommended by the SWGDRUG [15]. The concentration range analysed was 10 g/L to 0.1 g/L for 
mephedrone and 1 g/L to 0.1 g/L for MDAI and BZP. Repeats of n = 18 samples originated from three different 
stock solutions and were carried out alongside numerous reagent and drug controls to ensure accuracy of results. 
A grading system was developed to evaluate test results consistently [Table 2]. Each grade was allocated to be a 
positive or negative response. The crystals in the description refer to drug-reagent crystals only and do not include 
excess reagent crystallisation. The grading system was developed based on numerous repeats of various 
microcrystalline tests. There was no definite way to point out differences between neighbouring grades but an 
overall subjective impression was used to define the grades for the limit of detection study. 
In order to evaluate the limit of detection and to check for potential trends the results were plotted in a diagram of 
test response over number of experiments [Figure 4]. Grades of 4 and 5 were considered as true positives. The 
awarding of grade 3 was dependant on the test carried out. For example the mephedrone microcrystalline test 
always presented in either the one extreme of plenty of well-formed crystals or the other of nothing identifiable at 
all; BZP could only have a few well-formed crystals which were easily rated as a true positive due to the perfect 
habit of the crystal. 
Grades 1 and 2 were rated as negative as the presence of distorted crystals hinders correct identification of the 
sample when performing microcrystalline tests. Grade 0 was evaluated to be a true negative because of the 
absence of crystals. 
 
Table 2 
Grading system for evaluating the limit of detection of microcrystalline tests 
Grade Positive (P)/Negative (N) Description 
5 P numerous well-formed crystals 
4 P fair amount of well-formed crystals 
3 P few well-formed crystals 
2 N few distorted crystals 
1 N almost no crystals (if present distorted) 
0 N no crystals 
 
The mephedrone diagram [Figure 4a] shows a clear distinction of the given grades at concentrations of 5 g/L and 
2.5 g/L. Only little distinction could be seen between concentrations of 2.5 g/L and 1 g/L since some negative 
results (grade 0) with no crystal growth were detected at 2.5 g/L. Results which were graded as 1 and 2 were 
evaluated as negative despite crystal formation as they presented distorted and therefore could not be easily 
identified as unique mephedrone-reagent crystals.  
Overall, a clear distinction between the three tested concentrations could be made. The limit of detection could be 
narrowed down to approximately 3 g/L. At 2.5 g/L a few distorted crystals could be detected but identification as a 
positive test was borderline and somewhat difficult carried out by an inexperienced user. Based on these results 
the cut-off value for the mephedrone microcrystalline test was set to be 5 g/L as tests always gave true positive 
results. At a concentration of 1 g/L and below no mephedrone-reagent crystals formed [Table 3]. 
The optimum concentration for mephedrone crystal formation was around 10 g/L when using the mercury chloride 
reagent at a concentration of 10 g/L. Plenty of drug-reagent crystals formed within a couple of minutes when 
assisting the nucleation. If mephedrone is suspected in a sample but the above described crystals can not be 
obtained, it is recommended to test higher and lower concentrations of the sample solution as well as the 
powdered sample directly. 
The MDAI diagram [Figure 4b] shows a fairly clear distinction between true positive and negative results. 
Concentrations of 0.5 g/L always gave positive results being rated between 4 and 5 on the grading system. At 0.4 
g/L crystals would either grow in vast quantities and of perfect habit resulting in scores of 4 and 5 or in 10 out of 18 
tested times no crystal growth at all could be observed. Concentrations of 0.3 g/L were clearly detected as 
negatives rated between 0 and 2. Based on the scores given the limit of detection and the cut-off value were set at 
0.5 g/L [Table 3]. The optimum microcrystalline test concentration for MDAI was at 1 g/L as within a short time 
window plenty of large crystals grew upon assisted nucleation. This test can be easily evaluated when wet or dry 
but the dehydration of crystals resulting in a slightly different crystal habit needs to be taken in account. 
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The BZP diagram [Figure 4c] presented differently from the other tested drugs. No clear distinction between the 
tested concentrations could be seen. At concentrations of 0.3 g/L crystals of perfect quality would grow in large 
quantities. The results at a concentration of 0.2 g/L were unique from other microcrystal tests as very few but 
comparably large crystals in perfect habit would grow. At a concentration of 0.1 g/L the characteristic square 
crystals were absent but sometimes distorted and irregular flat plates could be observed. The limit of detection was 
determined to be 0.2 g/L and the cut-off value was set to be 0.3 g/L [Table 3]. The optimum microcrystalline test 
concentration for BZP was at 1 g/L. 
 
The evaluation of the limit of detection was somewhat subjective as to whether specific drug-reagent crystals had 
formed at critical concentrations around the limit of detection. At lower concentrations crystals formed much slower 
and often distorted in shape and habit. In order to keep results consistent it was decided to observe all 
microcrystalline tests when completely dry. However, this introduced the possibility of misinterpretation due to the 
masking of crystals of interest by excess reagent crystallisation or distortion of crystals based on dehydration of the 
test area. 
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Figure 4 
Graphic evaluation of the limit of detection for a) mephedrone, b) MDAI and c) BZP using microcrystalline testing with mercury chloride as 
reagent 
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Table 3 
Limit of detection and cut-off value for microcrystal detection of mephedrone, MDAI and BZP using the mercury 
chloride reagent 
Substance Limit of detection (g/L) Cut-off (g/L) 
Mephedrone 3.0 5.0 
MDAI 0.5 0.5 
BZP 0.2 0.3 
 
 
The caffeine study 
The effects of caffeine, as a cutting agent, on microcrystal development were investigated. Caffeine formed long 
needles when mixed with mercury chloride [Figure 3b]. The impurity of street samples was modelled by mixing 
volumes of caffeine and drug solutions on the slide (c = 1 g/L for BZP and MDAI, c = 10 g/L for mephedrone; c = 1 
g/L for caffeine) before adding the reagent; nucleation was assisted gently. 
Mephedrone, MDAI and BZP were tested in proportional content ranging from 10 to 90 % (v/v). Mephedrone 
crystals could be observed from 50 % (v/v) and greater mixed with caffeine, MDAI from 40 % (v/v) and BZP from 
20 % (v/v) [Table 4]. Caffeine crystals formed in all tested mixtures and could be easily identified. Only at MDAI 
percentages of 40 and above could the caffeine needles appear slightly distorted when being covered or joined 
with MDAI crystals. Since the habit of both MDAI- and caffeine-mercury chloride crystals is very different the 
deformation of crystals from the standard compound appearance did not influence the unequivocal identification of 
either substance. 
These results were comparable to tests conducted by ATR-FTIR on a solid MDAI standard mixed with caffeine at 
various percentages [6]. The dominance of caffeine peaks at 90% (w/w) disguised MDAI features in the spectrum 
in a way that identification of the active ingredient was impossible. 
 
Table 4 
Results of positive microcrystalline response for mephedrone, MDAI and BZP when altered with caffeine 
Substance Drug level necessary for positive identification 
(% v/v) 
Mephedrone ≥ 50 
MDAI ≥ 40 
BZP ≥ 20 
 
 
The mercury chloride reagent 
Mercury chloride controls crystallised in random three-dimensional grains and tablets. Microcrystalline tests where 
drug-reagent crystals predominantly grew within the periphery of the drop were likely to show some reagent-only 
crystals on the drying solvent front, especially at drug concentrations towards the limit of detection. Tests where 
drug-reagent crystals mostly originated from the border of the drop, reagent-only crystal formation was delayed 
until the test drop was about to dry out. 
 
In order to confirm that observed microcrystals were only formed when mercury (II) ions were present tests with 
mercury (II) iodide were carried out. Unlike the chloride, the iodide did not dissolve well in water with a solubility of 
7.4 g/100 mL at 20°C and solutions were therefore prepared in 100 % methanol. All drugs tested with mercury 
iodide were prepared in methanol to avoid precipitation of the reagent on contact with water. 
Microcrystalline tests are usually not carried out in solvents with a boiling point below 100°C as the rate of 
evaporation is too fast for crystals to develop to a decent size for certain identification. However, in order to 
determine whether the cation or anion is taking part in the crystal formation process, prematurely developed 
crystals were acceptable for comparison. 
Mephedrone formed bunches of colourless short needle rosettes when exposed to mercury iodide. Crystals did not 
develop into blades but overall resembled the three-dimensional structures observed when aqueous solutions of 
the drug is exposed to mercury chloride. MDAI produced serrated blades which developed to a smaller size 
compared to the aqueous mercury chloride reagent. Caffeine presented in needles which grew somewhat 
skeletonised and were very similar to the mercury chloride reagent. Only BZP produced too premature crystal 
structures of random grains to be judged a true positive. 
The similarity in crystal habit of 3 out of the 4 tested substances confirmed that indeed the mercury (II) ion takes 
part in forming the above described specific microcrystals. The detected changes in crystal habit were potentially 
related to the change of solvent rather than the associated halogen anion. 
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Application to internet purchased samples 
Seven legal high samples were purchased from three different websites in the second half of 2010 under the 
names of MDAI (3 products), 5-IAI, Benzo fury, NRG-3 and E2. Aqueous solutions (c = 1 g/L) of all 7 internet 
samples were tested with the mercury chloride reagent. Test drops were gently assisted for nucleation. 
Microcrystals for BZP and caffeine formed in two of the three MDAI samples as well as the Benzo fury, 5-IAI and 
NRG-3 products. The E2 sample produced simply caffeine crystals and only one of the MDAI samples formed the 
MDAI specific serrated blades. The absence of other crystals highlighted the reliability of the investigated 
microcrystal tests. Any other cutting agents present in the internet samples did not interfere with development of 
the drug-reagent crystals which in all cases formed first.  
Methanol extracts of these samples were analysed by FTIR-ATR and GC-MS and results were published early 
2011 [6]. The microcrystalline test results were in accordance with the findings ascertained from the analytical 
techniques [Table 5]. The presence of 3-TFMPP and potentially other unidentified substances did not hinder the 
crystal formation of MDAI, BZP and caffeine in the respective samples. 
 
Table 5 
Summarised results of the internet legal high samples purchased in the second half of 2010 
Product Website Active substances  
identified 
by microcrystalline test 
Active substances  
identified by FTIF/GC-MS 
MDAI 
 
www.benzofury.me.uk BZP 
caffeine 
BZP 
caffeine 
3-TFMPP 
Benzo fury www.benzofury.me.uk BZP 
caffeine 
BZP 
caffeine 
3-TFMPP 
5-Iodo- 
2-aminoindane 
(5-IAI) 
www.benzofury.me.uk BZP 
caffeine 
BZP 
caffeine 
3-TFMPP 
NRG-3 www.benzofury.me.uk BZP 
caffeine 
BZP 
caffeine 
3-TFMPP 
E2 www.benzofury.me.uk caffeine caffeine 
MDAI 
 
www.VIPlegals.com MDAI MDAI 
MDAI 
 
www.wide-mouth-
frog.com 
BZP 
caffeine 
BZP 
caffeine 
3-TFMPP 
 
CONCLUSION 
A rapid detection of mephedrone, MDAI and BZP using microcrystalline tests has been developed. Upon mixing 
with aqueous mercury chloride as a test reagent each drug formed specific microcrystals which were observed 
using transmitted light and phase contrast microscopy. Microcrystalline tests are versatile and can be carried out in 
as little as 10 minutes by dissolving a few granules of sample in 10 µL water on a slide, adding 10 µL of reagent 
and waiting a couple of minutes for crystals to develop. Detection via a microscope in less than a minute and 
comparing with crystals obtained using drug standards make microcrystalline tests a valuable contender in the race 
for rapid identification of seized samples. Moreover, no expensive and high maintenance analytical technology is 
needed to carry out successful tests.  
Tests with the cutting agent caffeine revealed that the specific microcrystal formation was not hindered for any of 
the investigated substances. The results were confirmed on internet bought samples of legal highs. BZP was 
detected alongside caffeine in mixtures also containing 3-TFMPP. Neither of the specific crystals were masked or 
influenced by the presence of other compounds in the mix.  
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